Physician profile
Joseph Biber
NPI 1457440620
$7,832.48
in general payments reported to CMS, 2019-2025
24 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,684 · 2020: $759 · 2021: $622 · 2022: $1,052 · 2023: $478 · 2024: $970 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,697 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.21 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $1,556.80 | 2019-2020 | |
| Alcon Vision LLC | $1,011.33 | 2019-2025 | Clareon, Unity, Tryptyr |
| US Retina LLC | $813.55 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $578.37 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $489.33 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $466.94 | 2019-2022 | |
| Abbvie INC. | $359.64 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $356.69 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Novartis Pharmaceuticals Corporation | $320.00 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $316.54 | 2019-2025 | Xelpros, Cequa |
| Dompe US, INC. | $229.48 | 2019-2025 | Oxervate |
| Rxsight INC | $201.14 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $191.61 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $177.54 | 2020-2025 | Acthar |
| Biotissue Holdings INC. | $169.88 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $141.15 | 2024-2025 | Vevye |
| Mallinckrodt Enterprises LLC | $115.79 | 2019 | |
| Kala Pharmaceuticals, INC. | $115.57 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $104.15 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $30.57 | 2024 | Tepezza |
| Shire North American Group INC | $24.44 | 2019 | |
| Aerie Pharmaceuticals, INC. | $24.34 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $18.88 | 2019 | |
| Astellas Pharma US INC | $18.75 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,869.91 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Biber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.